Matthew D. Galsky, MD

Articles

Dr Galsky on the FDA Approval of Nivolumab Plus Chemotherapy in Urothelial Carcinoma

March 29th 2024

Matthew Galsky, MD, discusses the significance of the FDA approval of frontline nivolumab plus chemotherapy patients with metastatic urothelial carcinoma.

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

March 10th 2023

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Dr. Galsky on Updated Findings From the CheckMate-274 Trial in Urothelial Cancer

February 17th 2023

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

Dr. Galsky on Clinical Trials That Addressed Key Questions in Urothelial Cancer

January 24th 2022

Matthew Galsky, MD, discusses clinical trials that addressed key questions in urothelial cancer.

Dr. Galsky on Sequencing Questions in Urothelial Cancer

June 23rd 2020

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

Dr. Galsky on the HCRN GU14-182 Study Results in Urothelial Cancer

August 6th 2019

Matthew D. Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab versus placebo in patients with metastatic urothelial cancer.

Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer

November 7th 2017

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

Atezolizumab Shows Promise of PD-1/PD-L1 Blockade in Metastatic Bladder Cancer

November 4th 2015

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.

Dr. Galsky on Biomarkers for Satraplatin in mCRPC

March 4th 2014

Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with mCRPC.

Dr. Galsky on the Role of Ipilimumab in Bladder Cancer

December 5th 2013

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

Dr. Galsky on Ipilimumab in Bladder Cancer

November 15th 2013

Matthew D. Galsky, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, explains the mechanism of action of ipilimumab in bladder cancer.

Dr. Galsky on a Post-Treatment Nomogram in Urothelial Cancer

February 20th 2013

Matthew D. Galsky, MD, from the Mount Sinai Medical Center Tisch Cancer Institute, discusses the development of a post-treatment prognostic model for patients with metastatic urothelial cancer.